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At the time the bacteria was speciated by 16S rRNA 
gene sequencing, the patient’s infection had already re-
solved. The clinical record does not document any ad-
ditional antimicrobial treatments she may have received 
from other clinical teams, including the infectious disease, 
transplant, and nephrology departments. This organism ap-
peared in 3 consecutive respiratory specimens collected 
when the patient’s symptoms worsened and raised con-
cerns among the attending clinical teams of potential infec-
tion with an innately drug-resistant species. However, we 
cannot definitively rule out the potential for colonization 
because a combination of factors likely led to clinical im-
provement in the patient. The organism was not detected in 
any subsequent bronchoscopies.
The genus Acetobacter encompasses a group of ace-
tic acid–producing organisms that can survive at low 
pH, largely occupy environmental niches, are used in-
dustrially to produce acetic acid products, and are not 
generally thought to be human pathogens (1). Analysis of 
the medical literature revealed 2 other documented clinical 
cases of A. indonesiensis infection among humans (2,3). 
The first case involved a patient with cystic fibrosis who 
had undergone a recent lung transplant (2). Similar to 
our case-patient, the patient had undergone bilateral lung 
transplants and A. indonesiensis pneumonia subsequently 
developed in both after a long course of broad-spectrum 
antimicrobial drugs. The second case involved a child with 
metachromatic leukodystrophy who was found to have A. 
indonesiensis bacteremia after extensive nursing care and 
invasive devices, including a port catheter thought to be the 
source of the infection (3). As with the patient we report, 
the patient in that report had been treated with a 2-week 
course of pipericillin/tazobactam, although her initial diag-
nosis was bacteremia rather than pneumonia. 
The case of A. indonesiensis human infection we re-
port and both previous cases we found in the literature 
involved chronically ill patients with complex medical 
conditions who were exposed to a long course of broad-
spectrum antimicrobial drugs. Although the source of the 
infecting organism in all 3 cases could not be definitively 
determined, the similarities between the cases raise the 
possibility that A. indonesiensis may represent a novel and 
emerging opportunistic and highly drug-resistant pathogen. 
Furthermore, the use of specific genotypic techniques such 
as 16S rRNA sequencing may aid in the identification of 
environmental organisms that are not identified by using 
traditional microbiological techniques.
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We describe a strain of Lassa virus representing a puta-
tive new lineage that was isolated from a cluster of hu-
man infections with an epidemiologic link to Togo. This 
finding extends the known range of Lassa virus to Togo.
Lassa virus is endemic to the West Africa countries of Guinea, Sierra Leone, Liberia, Mali, Côte d’Ivoire, and 
Nigeria (1–3). The virus causes Lassa fever, a hemorrhagic 
disease with a case-fatality rate ≈30% in the current hospital 
setting in West Africa. So far, 4 lineages of Lassa virus are 
firmly established: lineages I, II, and III circulate in Nigeria, 
and lineage IV circulates in Guinea, Sierra Leone, Liberia, 
Mali, and Côte d’Ivoire (1–3). Recently, strains from Mali 
and Côte d’Ivoire were proposed to represent a separate lin-
eage V (4). The newly discovered Lassa virus strain Kako 
from Hylomyscus pamfi rodents trapped in Nigeria is desig-
nated lineage VI for the purpose of this article (5).
Lassa virus has not been previously detected in humans 
or rodents in Togo; therefore, the virus was not considered 
endemic to this country. We describe a strain of Lassa vi-
rus representing a new lineage that was isolated from a 
cluster of human infections with an epidemiologic link to 
Togo (online Technical Appendix, https://wwwnc.cdc.gov/
EID/article/24/3/17-1905-Techapp1.pdf) (6,7). The clinical 
courses of the 3 case-patients and medical and public health 
interventions are described elsewhere (8–10).
The Lassa virus infections in the index case-patient, 
secondary case-patient 1, and secondary case-patient 2 
were confirmed by laboratory investigations at Bernhard 
Nocht Institute (Hamburg, Germany); Centers for Disease 
Control and Prevention (Atlanta, GA, USA); and Philipps 
University (Marburg, Germany), respectively. The viruses 
from all 3 patients were isolated in Vero E6 cell culture in 
the respective Biosafety Level 4 laboratories. Full-length 
virus sequences were generated directly from clinical 
specimens, from the isolates, or both using next-generation 
sequencing technology in combination with Sanger sequenc-
ing (sequences deposited into GenBank under accession nos. 
KU961971, KU961972, LT601601, LT601602, MF990886–
MF990889) (online Technical Appendix). The sequence 
from the index case-patient was submitted to GenBank on 
March 23, 2016, and immediately made publicly available 
to support the laboratory and public health response in Togo 
and the other affected countries. 
The virtually identical viruses from the 3 patients 
confirmed the transmission chains suggested by the epi-
demiologic data. Only the virus from secondary case-pa-
tient 2 showed differences in coding regions—a deletion 
of 3 nt and a nucleotide exchange in the polymerase (L) 
gene—from the viruses in the other 2 case-patients. These 
differences were confirmed by sequencing the virus in the 
clinical specimens. Differences among the 3 strains in the 
highly structured intergenic regions might represent arti-
facts created by the difficulty in sequencing these regions.
The phylogeny was inferred using BEAST2 (https://
www.beast2.org/) with nucleotide sequences of full-length 
nucleoprotein (NP), glycoprotein precursor (GPC), and L 
and Z genes of the Togo strain in conjunction with repre-
sentative sequences of Lassa virus and other Old World 
arenaviruses. The most stable reconstruction was obtained 
for the L gene with the Togo strain being placed in sister 
relationship with lineage II (all branches with posterior 
support values >0.97) (Figure). In the NP- and GPC-based 
phylogenies, the Togo strain clusters with lineages I and VI 
(Pinneo and Kako strains); however, the branching order is 
not well supported (posterior values 0.51–0.86) (Figure). 
The phylogeny based on the small Z gene further supports 
a relationship of the Togo strain with lineages I, II, and VI 
(online Technical Appendix Figure 1). The ambiguous po-
sition of the Togo strain relative to lineages I, II, and VI 
is consistent with a recombination analysis showing that 
most of the L gene sequence is related to lineage II, and 
NP and GPC comprise sequence stretches mainly related 
to lineages I and VI (online Technical Appendix Figure 2). 
This mosaic structure might be the result of recombination, 
reassortment, or both or might have evolved by chance.
The long branch (i.e., large phylogenetic distance) sepa-
rating the Togo strain from known lineages suggests that it 
represents a new lineage. Because Lassa virus lineages were 
originally established on the basis of uncorrected sequence 
distances (1), we used the same method here. The frequency 
distribution of pairwise amino acid distances in GPC, NP, and 
L between the Togo strain and all other Lassa virus strains 
perfectly overlaps with the distribution of distances between 
Lassa virus lineages I, II, III, IV, and VI indicating that the 
Togo strain is a separate lineage (online Technical Appen-
dix Table 1). However, we noted that the distance between 
the proposed lineage V and lineage IV rather corresponds to 
intralineage distances, and therefore, we considered lineage 
600 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 3, March 2018
RESEARCH LETTERS
V a subclade of lineage IV in our analysis (online Technical 
Appendix Table 1). We propose that formal recognition of 
Lassa virus lineages should be decided by the International 
Committee on Taxonomy of Viruses.
In conclusion, sequencing Lassa virus from a cluster of 
imported infections, with the index case-patient originating 
from Togo, reveals a new lineage of Lassa virus in West 
Africa. It seems to be related to lineage II or lineages I/VI, 
which are all circulating in Nigeria.
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Figure. Phylogeny of the Lassa virus strain from Togo, 2016. Phylogenetic trees were inferred by using BEAST2 (https://www.beast2.
org/) for full-length glycoprotein precursor (A), nucleoprotein (B), and polymerase (C) genes. The analysis included representative 
Lassa virus strains and other Old World arenaviruses (online Technical Appendix, https://wwwnc.cdc.gov/EID/article/24/3/17-1905-
Techapp1.pdf). Posterior support values are shown at the branches. Lassa virus lineages are indicated by roman numbers on the 
right. The branch for Mopeia and Mobala virus is shown schematically and the branches for the remaining Old World arenaviruses 
have been removed for clarity of presentation. The branches for the Togo strain and most closely related Lassa virus lineages are 
labeled (†, Togo; ‡, lineage II; *, lineages I and VI). The origins of the Lassa virus strains are abbreviated as follows: CIV, Côte 
d’Ivoire; GUI, Guinea; LIB, Liberia; MAL, Mali; NIG, Nigeria; SL, Sierra Leone. A color version of this figure is available online  
(https://wwwnc.cdc.gov/EID/article/24/3/17-1905-F1.htm).
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Knowing the mode of transmission of a disease can affect 
its control and prevention. Here, we identify 5 protozoan 
parasites with demonstrated presence in seminal fluid, only 
1 of which has been identified as a sexually transmitted dis-
ease among humans. 
A recent publication by Salam and Horby (1) identified at least 27 viruses present in human semen, some po-
tentially transmissible through sexual contact. Trichomon-
as vaginalis is a protozoan parasite recognized as sexually 
transmissible among humans (2). Similar to that which 
occurs with viruses, parasites could reach seminal fluid by 
passing from the bloodstream to the male genital tract or 
by directly infecting reproductive organs. In this context, 
more parasitic infections might also be transmitted sexu-
ally. Considering that parasitic diseases represent one of the 
most common infections worldwide, mainly in developing 
countries, sexual transmission of parasitic diseases could 
represent a major global problem in terms of public health.
To investigate whether parasites could enlarge the 
broad list of potential sexually transmitted infections 
(STIs), we conducted an online search on November 3, 
2017, by using PubMed (https://www.ncbi.nlm.nih.gov/
pubmed/), EMBASE (https://www.elsevier.com/solutions/
embase-biomedical-research), and the Cochrane Library 
(http://www.cochranelibrary.com/) with no language re-
strictions. We used the terms “parasites OR parasitic dis-
ease” and “semen OR seminal plasma.” We also made a 
manual search of the references of selected reports. Two 
reviewers independently screened the 512 returned results 
of titles, abstracts, and full text in selected articles.
Our search resulted in 5 parasite species with demon-
strated presence in seminal fluid of humans: Entamoeba 
hystolytica (3), Schistosoma haematobium (4), Tricho-
monas vaginalis (2), Trypanosoma cruzi (5), and Toxo-
plasma gondii; the latter has been documented as sexually 
transmitted among animals, but not humans (6) (Table). E. 
hystolytica is a worldwide anaerobic protozoan; its preva-
lence increases disproportionately in areas of poor sanita-
tion in low-income countries. E. hystolytica has been iden-
tified in the testicles, epididymis, and seminal fluid (3,7), 
can reportedly cause infertility as a result of reproductive 
organ damage (8), and is transmitted by sexual contact 
(both oral-anal and oral-genital sexual practices) (7).
Urogenital schistosomiasis caused by S. haematobium 
infection affects male and female children and adults main-
ly in Africa, the Middle East, and Corsica, France. After 
the larval S. haematobium cercarias penetrate intact skin 
from contaminated fresh water, they migrate and mature 
into adult worms, predominantly in the venous plexus of 
the bladder. These worms can then travel to the seminal 
vesicles and prostate, causing local pathology (9). S. hae-
matobium eggs have been found in up to 43% of 44 semen 
samples and in 33.3% of cervix biopsies obtained from 36 
women from endemic area populations (4,10); neverthe-
less, sexual transmission has not been reported.
T. vaginalis protozoa are the most common nonviral 
STI in the world, and incidence is increasing (11). The gen-
ital tract of humans is the natural habitat for this parasite, 
which can cause urogenital tract infection. T. vaginalis has 
been identified in seminal fluid and has been related to de-
creased sperm quality (2,8).
Chagas disease is caused by T. cruzi protozoa and af-
fects nearly 6 million persons in Latin America countries. 
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